Synopsis:
As of September 2025, Tata Mutual Fund added fresh stakes in a pharma sector company.
Tata Mutual Fund, part of the trusted Tata Group, was set up in 1994 and offers a wide range of investment options across equity, debt, and hybrid funds. Known for its disciplined approach and focus on long-term wealth creation, it helps investors meet their financial goals with trust and stability. As per corporate shareholdings data for September 30, 2025, it publicly holds 58 stocks with a total net worth of over Rs 11,435.1 Cr.
With a market capitalization of Rs. 13,750.82 crore, the shares of Granules India Limited is trading at Rs. 566.65, up by 3.26 percent from its previous close of Rs. 548.75.
What’s the News?
As of September 2025, Tata Mutual Fund – Tata Aggressive Hybrid Fund acquired a fresh 1.11 percent stake in Granules India Limited by purchasing 26.86 lakh shares, which is currently worth ~Rs. 147.70 crore.
As of September, 2025, the Tata Aggressive Hybrid Fund has a total fund size of Rs. 4,011.18 crore with investment in 90 Companies. Their portfolio holdings are 74 percent in equity, 22.8 percent in debt and 3.2 percent in cash.
Also Read: Telecom stock jumps after securing ₹303 Cr order to supply optical fiber cables
About the Company
Granules India Limited, headquartered in Hyderabad, manufactures and sells active pharmaceutical ingredients (APIs), formulation intermediates, and finished dosages both in India and internationally.
Its products include tablets, capsules, oral solutions, and powders across a wide range of therapeutic categories such as anti-diabetic, anti-cancer, anti-viral, CNS, cardiovascular, and anti-inflammatory treatments. Founded in 1984, the company also develops specialized peptides and amino acid derivatives.
A return on equity (ROE) of about 13.9 percent, a return on capital employed (ROCE) of about 15.1 percent and debt to equity ratio of 0.39 demonstrate the company’s financial position. At the moment, the company’s P/E ratio is 27.9x lower as compared to its industry P/E 32.8x.
The company reported Q1FY26 revenue of Rs. 1,210 cr, up 2.5 percent YoY from Rs. 1,180 cr and 1.1 percent QoQ from Rs. 1,197 cr in Q4FY25. Profit declined to Rs. 113 cr, down 16.3 percent YoY from Rs. 135 cr and 25.7 percent QoQ from Rs. 152 cr, reflecting margin pressure despite modest revenue growth.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
